Loading...
Market
What will be Soleno Therapeutics' next major strategic move by end of 2025?
2
Resolution / Starting Odds
Launch a new drug • 25%
Enter a new partnership • 25%
Expand into new markets • 25%
No major changes • 25%
Official announcements from Soleno Therapeutics
Story
Soleno Therapeutics' Stock Soars 12% to 52-Week High as FDA Backs Prader-Willi Syndrome Drug
Oct 8, 2024, 03:17 PM
Soleno Therapeutics has announced a regulatory update on its DCCR (diazoxide choline) Extended-Release Tablets for the treatment of Prader-Willi Syndrome. The FDA has decided not to require an advisory committee meeting for the drug, indicating a strong outlook for its approval. This decision has positively impacted Soleno Therapeutics' stock, which has increased by 12% to a new 52-week high and by 7.9% pre-market. The company has also received Priority Review for its drug candidate, further supporting the potential for approval. The lack of an advisory committee meeting reduces potential uncertainty, and the market is optimistic about the drug's approval due to the strong data supporting its efficacy and the unmet need for treatments addressing PWS-associated hyperphagia.
View original story
Similar markets
Launches new product • 25%
Announces partnership • 25%
Pursues merger/acquisition • 25%
No major move • 25%
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly Underperform • 25%
Outperforms sector • 25%
Performs similarly to sector • 25%
Underperforms sector • 25%
No significant change • 25%
Above $10 • 25%
$8 to $10 • 25%
$6 to $8 • 25%
Below $6 • 25%
Pharmaceutical company • 25%
Government agency • 25%
Research institution • 25%
Other • 25%
Merger or acquisition • 25%
New major partnership • 25%
Launch of another Phase 3 trial • 25%
Other • 25%
Approved • 25%
Not Approved • 25%
Conditional Approval • 25%
Approval Delayed • 25%
New Alzheimer's drug candidate announced • 25%
Focus shifts to different therapeutic area • 25%
Company gets acquired • 25%
Continues current operations without major changes • 25%
Approved • 25%
Approved with conditions • 25%
Rejected • 25%
Review extended • 25%